01—Abstract
Summary
Summary of the 10-Q filed May 9, 2024. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported total revenue of $1,011.6 milliona for the three months ended March 30, 2024, down $17.8 million, or 1.7%, from $1,029.4 million in the prior-year quarter.
The decline was driven mainly by lower volume in the DSA segment, partly offset by higher RMS revenue (including the Noveprim acquisition) and higher Manufacturing revenue. Operating income fell to $126.0 millionb, a 12.5% operating margin, versus $167.9 million and 16.3% a year earlier, reflecting lower revenue, higher staffing and operating costs, and restructuring charges of about $17 million. Net income available to common shareholders decreased to $73.0 million from $103.1 million, though diluted EPS as presented was $1.30 versus $2.01 after noncontrolling interest and dividend adjustments.
Cash flow from operations improved to $129.9 millionc from $109.4 million, driven by timing of vendor payments and improvements in revenue-related accounts. Total debt and finance leases were $2.68 billion at quarter end, with cash and cash equivalents of $327.0 million. The company repurchased no shares under its $1.3 billion program during the quarter, leaving $129.1 million authorized, and management stated the company believes existing funds are sufficient for foreseeable operations.
The filing also details ongoing U.S. government investigations by the DOJ, USFWS and SEC related to non-human primate shipments from Cambodia, a securities class action, and a derivative lawsuit. The company states it believes the concerns are without merit, cannot predict outcomes, and cannot reasonably estimate potential exposure for the class action or derivative suit. Inventory tied to the Cambodia-sourced shipments was approximately $27 milliond.
02—Key points
Key Highlights
- Total revenue of $1,011.6 million, down $17.8 million (1.7%) year over year, with DSA revenue down $56.9 million (8.6%) on lower volume
- RMS revenue rose $21.1 million (10.6%), principally from the Noveprim acquisition, which contributed $15.1 million
- Operating income of $126.0 million (12.5% margin) versus $167.9 million (16.3% margin) a year earlier
- Restructuring costs of approximately $17 million in the quarter, with about $70 million of annualized cost savings expected from actions taken and planned
- Net cash from operations of $129.9 million versus $109.4 million, driven largely by working capital timing
- No share repurchases in the quarter; $129.1 million remains under the $1.3 billion authorization
- Ongoing DOJ, USFWS and SEC investigations over Cambodian non-human primate shipments, plus a securities class action and derivative lawsuit; the company says it believes the claims are without merit
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2024, Charles River Laboratories International kept $0.07.
- Revenue$1.01B100.0%
- Cost of revenue−$666.7M65.9%
- Gross profit$344.8M34.1%
- Operating costs−$218.9M21.6%
- Operating income$126.0M12.5%
- Interest, other & tax−$58.6M5.8%
- Net income$67.3M6.7%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed May 9, 2024Financial Statements
| Revenue | $1.01B |
| Cost of Revenue | $666.72M |
| Gross Profit | $344.84M |
| SG&A Expenses | $186.29M |
| Operating Income | $125.98M |
| Interest Expense | $35.00M |
| Net Income | $67.33M |
| EPS (Basic) | $1.31 |
| EPS (Diluted) | $1.30 |
| Shares Outstanding (Basic) | 51.44M |
| Shares Outstanding (Diluted) | 51.84M |
05—Questions
Frequently Asked Questions
Why did operating income decline so sharply this quarter?
Management attributed the decrease primarily to lower revenue, mainly in the DSA business due to decreased volume, along with higher staffing and operating costs across all businesses and charges for restructuring, including severance and asset impairments. DSA operating income fell $56.6 million to $114.8 million, and unallocated corporate costs rose $19.6 million to $65.7 million, primarily from higher variable compensation and severance.
How is the company's liquidity position?
Cash and cash equivalents were $327.0 million at March 30, 2024, up from $276.8 million at December 30, 2023. Total debt and finance leases were $2,676.7 million, with a revolving facility balance of $1,133.0 million. Management believes existing funds, combined with operating cash flow and financing access, are sufficient to fund operations for the foreseeable future.
What is the status of the non-human primate investigations?
The DOJ and USFWS are conducting a criminal investigation and a parallel civil investigation, and the SEC Enforcement Division has also made an inquiry that was augmented with a document subpoena. The company is cooperating, has voluntarily suspended future shipments of non-human primates from Cambodia to the U.S., and states it cannot predict the timing, outcome or possible impact, including any fines, penalties or liabilities.
Did the Noveprim acquisition affect results this quarter?
Yes. The Company acquired an additional 41% interest in Noveprim Group on November 30, 2023, bringing its ownership to 90%. The filing states Noveprim contributed $15.1 million to RMS revenue in the quarter. The total preliminary purchase price was $374.8 million, and the company holds a call option on the remaining 10% with a redemption value of $47.0 million to $54.0 million depending on timing.
06—Continue